COMMENTARY

Commentary: A New Classification for von Willebrand Disease

By J. Evan Sadler and Harvey R. Gralnick

VON WILLEBRAND DISEASE (VWD) is the most common inherited human bleeding disorder. Approximately 125 individuals per million population have symptomatic VWD, and this is roughly twice the prevalence of hemophilia A. Asymptomatic inherited defects in von Willebrand factor (VWF) function are extremely common, and are detectable in nearly 1% of unselected persons. Within the last decade dozens of new variants of VWD have been identified, based on abnormalities in either the biochemical properties of the protein or the nucleotide sequence of the gene. As a result, the evolving nomenclature for VWD has become unwieldy. At last count, there were more than 14 reported varieties of type I VWD (having a normal-appearing distribution of VWF multimers) and more than 13 reported varieties of type II VWD (characterized by the absence of large VWF multimers). The remaining category, type III VWD, is associated with the virtual absence of detectable VWF.

Recent progress in the characterization of mutations that cause VWD has provided the necessary stimulus to readdress the issue of how VWD is classified. In response to this situation, a revised classification was developed and endorsed last year by the Subcommittee on von Willebrand Factor of the International Society on Thrombosis and Haemostasis (ISTH). This simplified scheme is based primarily on the phenotype of the VWF protein that is present in patient plasma and platelets. In this commentary we will discuss the conceptual framework and goals of the new classification. The major features of the classification are listed in Table 1. A more detailed discussion, as well as a correspondence table that relates the new classification to previous nomenclature, can be found in the Subcommittee report.

The principles underlying the new classification derive from several sources, beginning with the first splitting of nomenclature, can be found in the Subcommittee report. The principles underlying the new classification derive from several sources, beginning with the first splitting of nomenclature, can be found in the Subcommittee report.

The key simplification in the new classification of VWD is the definition of major categories strictly in terms of quantitative or qualitative defects, and the further division of qualitative defects in terms of discrete pathophysiologic mechanisms.

From the Howard Hughes Medical Institute, the Departments of Medicine and Biochemistry & Molecular Biophysics, The Jewish Hospital of St Louis, Washington University School of Medicine, St Louis, MO; and Hematology Service, National Institutes of Health Clinical Center, Bethesda, MD.

Submitted May 25, 1994; accepted May 25, 1994.

Address reprint requests to J. Evan Sadler, MD, PhD, Howard Hughes Medical Institute, Washington University, 660 S Euclid, Box 8022, St Louis, MO 63110.

© 1994 by The American Society of Hematology.

0006-4971/94/8403-0046$3.00/0

**Table 1. A Revised Classification of VWD**

1. All VWD is caused by mutations at the VWF locus.
2. Type 1 VWD refers to partial quantitative deficiency of VWF. Type 2 VWD refers to qualitative deficiency of VWF. Type 3 VWD refers to virtually complete deficiency of VWF.
3. Type 2A VWD refers to qualitative variants with decreased platelet-dependent function that is associated with the absence of high-molecular-weight VWF multimers.
4. Type 2B VWD refers to qualitative variants with increased affinity for platelet glycoprotein Ib.
5. Type 2M VWD refers to qualitative variants with decreased platelet-dependent function that is not caused by the absence of high-molecular-weight VWF multimers.
6. Type 2N VWD refers to qualitative variants with markedly decreased affinity for factor VIII.
7. When recognized, a mixed phenotype caused by compound heterozygosity is indicated by separate classification of each allele separated by a slash (/).
8. For the description of mutations, numbering systems are suggested for amino acids and nucleotides.

**THE REVISED CLASSIFICATION**

A basic tenet of the new classification is that VWD is caused only by mutations at the VWF locus. Potential mimics of VWD that arise through some other mechanism can be designated as a particular form of "pseudo-VWD" if they are inherited, or as "von Willebrand syndrome" if they are acquired. The revised classification distinguishes partial quantitative (type 1), qualitative (type 2), and total quantitative (type 3) deficiency. The minimal change in the nomenclature from Roman to Arabic numerals differentiates the new categories from those of previous classifications, but preserves the oldest and most useful distinctions made by earlier classifications of VWD, starting with Holmberg and Nilsson. Type 1 VWD is often dominant, type 2 VWD may be dominant or recessive, and type 3 VWD is recessive. In general, quantitative deficiencies will correlate with promoter, nonsense, and frameshift mutations, and with large deletions. Qualitative deficiencies will correlate with missense mutations and small in-frame deletions or insertions. No distinction is made between patients with typical dominantly inherited type 1 VWD and the occasional phenotypically similar, symptomatic relatives of patients with type 3 VWD; both are classified as type 1 VWD.

Type 2 VWD is further subdivided according to the apparent primary cause of the hemostatic defect. Because the largest VWF multimers per se are required for normal platelet adhesion to sites of vascular injury, any mechanism that causes a deficiency of large multimers may result in VWD. Such variants are classified under type 2A, which may be considered to encompass nonspecific defects in multimer size. Type 2A corresponds roughly to the previous "type IIA" variant, but also includes a variety of other subtypes that have in common the loss of large, hemostatically effective VWF multimers (Fig 1B). Defective platelet adhesion also may result, paradoxically, from increased binding of VWF to platelets. This category, designated as type 2B, is approximately the same as the previous "type IIB," but

![Fig 1. Multimer patterns for plasma VWF from patients with selected variants of VWD. Samples were electrophoresed on a 1.3% agarose gel in the presence of sodium dodecyl sulfate, and VWF multimers were visualized with a radiiodinated anti-VWF antibody. (A) The type of VWD is indicated with the terminology of the revised classification given first, followed by the previous classification in parentheses. Lane 1, normal plasma; lane 2, VWD type 1 (formerly type I); lane 3, VWD type 2A (formerly type IB); lane 4, normal plasma. (B) Lanes N contain normal plasma samples. In the revised classification, all of the patterns represented in lanes 1 through 6 are designated VWD type 2A. In the terminology of the previous classification these types of VWD were designated as follows: lane 1, type IIC; lane 2, type IIe; lane 3, type IIC (sibling of patient of lane 1); lane 4, type IIID; lane 5, type IIe (sibling of patient of lane 2); lane 6, type IIA.](image-url)
includes some patients with relatively normal VWF multimer distribution.

The two remaining secondary categories reflect the recent progress in defining the biochemical interactions of VWF in molecular detail. A few patients exhibit markedly decreased platelet-dependent VWF function or other evidence of a qualitative abnormality despite a relatively normal multimer distribution, and these patients are designated as type 2M ("M" for "multimer"). Some of these patients have mutations in domains of VWF that are required for binding to platelet glycoprotein Ib. The last variant, type 2N, is characterized by failure of VWF to bind factor VIII. Because this interaction is required for the normal survival of factor VIII in the circulation, these patients have factor VIII deficiency associated with normal platelet adhesion. The name "type 2N" reflects the origin in Normandy, France, of one of the first families to be identified with this disorder. Recognition of this autosomal mimic of hemophilia is required for patients to receive appropriate blood component therapy and genetic counseling.

In addition to defining specific diagnostic categories, the new classification suggests a nomenclature for compound heterozygous patients. Inherited defects of VWF function are extremely common, and the accidental coinheritance of otherwise "recessive" VWD alleles is proving to be common also. Awareness of the possibility of compound heterozygosity is important because genetic counseling in such families can be substantially different than for dominant type zygosity is important because genetic counseling in such first-degree relatives also. Awareness of the possibility of compound heterozygosity is important because genetic counseling in such families can be substantially different than for dominant type 1 VWD.

Finally, numbering systems are suggested for the description of nucleotide and amino acid substitutions (Table 1). These recommendations will be useful mainly for the reporting and tabulation of molecular defects in VWD.

DISCUSSION

The revised classification preserves many desirable features of previous classifications, but is substantially simpler. There are two levels of the classification: primary (types 1, 2, and 3) and secondary (A, B, M, N). These are combined to yield a total of only six diagnostic categories, compared with more than 28 previously named subtypes. Additional descriptors may be suggested by the reporting scientist (ie, toponyms), but are not part of the formal diagnostic name.

As described in the Subcommittee report, the classification of a new patient with VWD can be approached by focusing on pathophysiology. Does the patient bleed because of a quantitative (type 1 or 3) or qualitative (type 2) VWF defect? If qualitative, does the defect affect platelet function or factor VIII binding (type 2N)? If the defect affects platelet function, is it caused by loss-of-function or, paradoxically, by gain-of-function (type 2B)? If loss-of-function, is this caused nonspecifically by the absence of large multimers (type 2A) or not (type 2M)?

Some conceptual problems are necessarily shared by any practical, concise classification of VWD. No matter how the categories are defined, some patients will not fit cleanly into any of them. For example, the distinction between type 1 and type 2M depends on differentiating normal and abnormal VWF primary, secondary, and tertiary structures. The existing analytical methods are not particularly sensitive, so errors in classification will occur. Similarly, the distinction between type 2A and type 2M depends on recognizing the absence of high-molecular-weight VWF multimers, but how much of a decrease in multimer size is required? These problems are not peculiar to the new classification, however, because the distinction between the previous categories "type I" and "type II" depended on the same assays.

One unavoidable problem with any pathophysiologic classification of VWD is that a mutation could, in principle, cause a qualitative VWF defect by more than one mechanism. If a predominant mechanism cannot be identified, such a patient can be classified simply as "type 2." This is the sort of patient for whom an associated descriptive name would be especially useful, to serve as a reminder of the unique and complex phenotype.

A goal of the new classification is to minimize the number and the clinical significance of hard-to-classify variants, while maximizing the correlation of subtypes with the response to therapy with 1-deamino-8-D-arginine vasopressin (DDAVP) or plasma fractions. In this respect, it should succeed at least as well as previous classifications. Most responders to DDAVP will have type 1 VWD, some will have type 2A or 2M VWD, and very few will have type 2N or type 3 VWD. Most clinicians will elect not to use DDAVP in type 2B VWD, although this appropriately has been useful in some patients. Highly purified factor VIII preparations may lack sufficient VWF to stabilize their factor VIII in vivo. Consequently, such preparations may exhibit poor recovery and shortened plasma half-life when administered to patients with VWD type 2N or type 3. For these subtypes of VWD, factor VIII preparations that contain substantial amounts of normal VWF would be preferred.

The process of developing this classification was instructive for all the participants. As a result of this exercise, the critical gaps in our knowledge of VWD seem to be better defined. However, the new scheme will endure only if clinicians actually apply it to patients and also find it useful to predict clinical behavior. Of course, our hope is that this will be the case. By working through the Subcommittee on von Willebrand factor, reaching a consensus was surprisingly easy. Therefore, this ISTH mechanism should provide a regular, international forum to insure that the classification of VWD can evolve to reflect new knowledge.

REFERENCES

Commentary: a new classification for von Willebrand disease

JE Sadler and HR Gralnick